COVID-19 Curbside Consults

Cytokine storm release syndrome and the prospects for immunotherapy with COVID-19, part 4: The role of JAK inhibition

Leonard H. Calabrese, DO, Tiphaine Lenfant, MD and Cassandra Calabrese, DO
Cleveland Clinic Journal of Medicine March 2021, DOI: https://doi.org/10.3949/ccjm.87a.ccc060

Article Information

DOI 
https://doi.org/10.3949/ccjm.87a.ccc060
PubMed 
32847819
Published By 
Cleveland Clinic Journal of Medicine
Print ISSN 
0891-1150
Online ISSN 
1939-2869
History 
  • Published online March 1, 2021.

Article Versions

Copyright & Usage 
Copyright © 2021 The Cleveland Clinic Foundation. All Rights Reserved.

Author Information

  1. Leonard H. Calabrese, DO⇑
  1. Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, Cleveland Clinic
  1. Correspondence:
    Leonard H. Calabrese, DO, Department of Rheumatic and Immunologic Diseases, A50, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; calabrl{at}ccf.org
  1. Tiphaine Lenfant, MD
  1. Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute Department of Infectious Disease, Cleveland Clinic
  2. Assistance Publique des Hôpitaux de Paris, Université de Paris
  3. Hôpital européen Georges Pompidou, Service de médecine interne, Paris, France
  1. Cassandra Calabrese, DO
  1. Department of Rheumatic and Immunologic Diseases, Orthopedic & Rheumatologic Institute, and Department of Infectious Disease, Cleveland Clinic
Back to top

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section